Letter: Afferent blockage, oestrogenic therapy, and malignancy.
D000328:Adult; D002471:Cell Transformation, Neoplastic / Q000187:drug effects; D004967:Estrogens / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects; D037102:Lectins; D008214:Lymphocytes / Q000187:drug effects; D008297:Male; D009369:Neoplasms / Q000188:drug therapy* / Q000276:immunology; D009475:Neurons, Afferent / Q000187:drug effects; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000276:immunology; D011956:Receptors, Cell Surface / Q000187:drug effects; D013936:Thymidine; D014316:Tritium
D004967:Estrogens; D037102:Lectins; D011956:Receptors, Cell Surface; D014316:Tritium; D013936:Thymidine